William H. Wildgoose
Papers
2
Total Citations
42
H-Index
2
About
William H. Wildgoose is a leading clinical researcher in urologic oncology, with a focused expertise in the management of small renal masses (SRMs). His work directly addresses the critical challenge of overtreatment in kidney cancer, where incidentally detected SRMs often have an indolent natural history. Dr. Wildgoose’s major contribution is the development and execution of the Nephron Sparing Treatment (NEST) trial, a pioneering feasibility cohort-embedded randomised controlled trial. This innovative study directly compares percutaneous cryoablation to robot-assisted partial nephrectomy, providing high-level evidence in a field historically plagued by poor recruitment to classical RCTs. His protocol (2019) and primary results paper (2023) have each garnered 21 citations, demonstrating immediate impact on clinical practice and trial methodology. By establishing the feasibility of this embedded trial design, Dr. Wildgoose has paved the way for future definitive studies, directly influencing how urologists weigh oncologic control against the health burden of surgical intervention. His work is essential reading for any researcher or clinician navigating the evolving landscape of nephron-sparing surgery.
Research Focus
Key Achievements
Top Papers
- 1
- 2